Subscribe to RSS
DOI: 10.1055/s-2003-43142
© Georg Thieme Verlag Stuttgart · New York
Bipolare Depression: L-Thyroxin-Augmentation als Möglichkeit einer medikamentösen Behandlung
Publication History
Publication Date:
24 October 2003 (online)
Zusammenfassung
Der Einsatz von Schilddrüsenhormonen in der Behandlung affektiver Erkrankungen ist seit mehr als 40 Jahren Gegenstand wissenschaftlicher Untersuchungen. Bei Patienten mit therapierefraktären affektiven Erkrankungen zeigte sich in neueren klinischen Studien ein gutes und vielversprechendes Ansprechen auf die adjuvante Gabe von L-Thyroxin in supraphysiologischer Dosierung. Um die Wirksamkeit und Sicherheit von hochdosiertem L-Thyroxin weiter zu untersuchen, wurde eine multizentrische, doppelblinde, plazebo-kontrollierte Studie unter der Leitung der Autoren kürzlich begonnen. Über einen Zeitraum von zwei Jahren sollen 80 Patienten mit einer bipolaren Depression an sechs verschiedenen Studienzentren eingeschlossen werden, die entweder hochdosiert L-Thyroxin als Augmentationsbehandlung oder Plazebo erhalten.
Summary
Since the early 1960s, the use of thyroid hormones in the treatment of affective disorders has been investigated repeatedly. The therapeutic and prophylactic effects resulting from adjunctive use of supraphysiological doses of L-thyroxine appears to be one of the promising strategies in severely ill and refractory patients with bipolar disorders. To further assess safety and efficacy of treatment with high-dose L-thyroxine, a multicenter, double-blind, placebo-controlled trial has recently been initiated by the authors. Patients with bipolar depression will be included in 6 study sites and be randomly assigned to either receive L-thyroxine 300 μg per day or placebo.
Key Words
Levothyroxine - thyroid hormones - bipolar mood disorder - depression
Literatur
- 1 Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001; 158 1617-1622
- 2 Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. Arch Gen Psychiatry. 1996; 53 842-848
- 3 Bauer M, Adli M, Bschor T, Heinz A, Rasgon N, Frye M, Grunze H, Kupka R, Whybrow PC. Clinical applications of levothyroxine in refractory mood disorders. Clin Appr Bipol Disord. 2003; 2 49-56
- 4 Bauer M, Baur H, Berghöfer A, Ströhle A, Hellweg R, Müller-Oerlinghausen B. et al. . Effects of supraphysiological thyroxine adminstration in healthy controls and patients with depressive disorders. J Affect Disord. 2002; 68 285-294
- 5 Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R, Adli M, Baethge C, Müller-Oerlinghausen B. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology. 2002; 27 620-628
- 6 Bauer M, Hellweg R, Gräf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology. 1998; 18 444-455
- 7 Bauer M, London ED, Rasgon N, Berman SM, Frye MA, Altshuler L, Mandelkern MA, Bramen J, Woods R, Mazziotta JC, Whybrow PC. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in women with bipolar disorder. Eingereichtes Manuskript.
- 8 Bauer M, Szuba MP, Whybrow PC. Psychiatric and behavioral manifestations of hyperthyroidism and hypothyroidism. In: Wolkowitz OM, Rothschild AJ, eds. Psychoneuroendocrinology. The Scientific Basis of Clinical Practice. American Psychiatric Press, Inc., Washington D.C. 2003; 419-444
- 9 Bauer M, Whybrow PC. Thyroid hormone, brain and behavior. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT (eds). Hormones, brain and behavior. Academic Press, San Diego. 2002; 239-264
- 10 Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder II. Treatment of refractory rapid cycling with high-dose levothyroxine: A preliminary study. Arch Gen Psychiatry. 1990; 47 435-440
- 11 Bauer MS, Whybrow PC, Winokur A. Rapid cycling bipolar affective disorder I. Association with grade I hypothyroidism. Arch Gen Psychiatry. 1990; 47 427-432
- 12 Baumgartner A. Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research. International Journal of Neuropsychopharmacology. 2000; 3 149-165
- 13 Bschor T, Bauer M. Schilddrüsenhormone in der Behandlung affektiver Störungen. Psychopharmakotherapie. 1998; 5 94-98
- 14 Extein I, Pottash ALC, Gold MS. Does subclinical hypothyroidism predispose to tricyclic-induced rapid mood cycles?. J Clin Psychiatry. 1982; 43 290-291
- 15 Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Research. 1990; 32 241-251
- 16 Stancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Arch Gen Psychiatry. 1982; 39 311-312
- 17 Sullivan GM, Hatterer JA, Herbert J, Chen X, Roose SP, Attia E. et al. . Low levels of transthyretin in the CSF of depressed patients. Am J Psychiatry. 1999; 156 710-715
- 18 Whybrow PC, Bauer M. Behavioral and psychiatric aspects of thyrotoxicosis. In: Braverman LE, Utiger RD (eds). The Thyroid. A Fundamental an Clinical Text (8th edition). Lippincott-Raven, Philadelphia. 2000; 673-678
Korrespondenzadresse:
PD Dr. Dr. Michael Bauer
Klinik für Psychiatrie und Psychotherapie, Charité-Universitätsmedizin Berlin, CCM
Schumannstr. 20/21
10117 Berlin